Blood Tests on Ozempic or Mounjaro
The complete monitoring panel for GLP-1 receptor agonists — what to check, when to check it, and which results should send you back to your GP urgently.
The Quick Answer
GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) are among the most prescribed medications in Australia right now — for type 2 diabetes management and weight loss. They work by mimicking a gut hormone that regulates appetite, insulin release, and blood sugar.
Regular blood test monitoring is essential — not because these drugs are dangerous, but because they are powerful. Blood tests confirm the medication is working (falling HbA1c, improving lipids), detect rare but serious side effects early (pancreatitis, kidney stress), and identify nutrient deficiencies that develop from reduced food intake over time.
How GLP-1 Drugs Work and Why Monitoring Matters
Glucagon-like peptide-1 (GLP-1) is a hormone released from your gut after eating. It tells your pancreas to release insulin, tells your brain you are full, and slows down how fast food leaves your stomach. Ozempic and Mounjaro are synthetic versions of GLP-1 (with tirzepatide also mimicking GIP, a related hormone) that last a full week from a single injection.
Because these drugs affect so many systems — pancreas, liver, kidneys, gut motility, and appetite — they have the potential to both improve and occasionally stress multiple organ systems. Blood tests let you and your GP see exactly what is happening under the surface: whether your blood sugar has genuinely improved, whether your kidneys are handling the reduced fluid intake, and whether your liver is improving as expected with weight loss.
Mounjaro (tirzepatide) is generally more potent than Ozempic and produces larger reductions in HbA1c and body weight. This means the monitoring schedule is similar but the magnitude of change — and the risk of hypoglycaemia when combined with other diabetes drugs — is greater.
Key Blood Tests to Monitor
Australian reference ranges from RCPA (Royal College of Pathologists of Australasia) guidelines. Your own target ranges may differ based on age, other conditions, and your GP's clinical judgement.
HbA1c
Primary measure of blood sugar control over 3 months. The main reason most people are on Ozempic or Mounjaro. Expect a 10-20 mmol/mol drop in the first 3-6 months. Check at baseline and every 3-6 months.
Fasting glucose
Day-to-day blood sugar snapshot. Useful between HbA1c checks. GLP-1 drugs reduce fasting glucose by slowing gastric emptying and stimulating insulin release.
Lipase and amylase
Screen for pancreatitis. Critical safety marker. Elevated lipase (more than 3x upper limit of normal) with abdominal pain requires urgent GP review. Mild asymptomatic rises are common and may not need action.
LFTs (ALT, AST, GGT, bilirubin)
Monitor for fatty liver improvement and rule out drug-induced liver injury. GLP-1 drugs reduce liver fat in non-alcoholic fatty liver disease (NAFLD). ALT and AST typically improve over 6-12 months of treatment.
eGFR and creatinine
Assess kidney function, especially in dehydration from nausea. Dehydration from frequent nausea or vomiting can transiently worsen kidney function. Check if vomiting is significant or prolonged. GLP-1 drugs are generally kidney-protective long term.
Lipid panel (total cholesterol, LDL, HDL, triglycerides)
Confirm expected lipid improvements. Triglycerides typically fall 15-25%. LDL usually drops modestly. If lipids worsen, review diet and consider whether the medication is being absorbed adequately given gastrointestinal side effects.
TSH (thyroid stimulating hormone)
Screen for thyroid dysfunction including C-cell concerns. Annual TSH recommended. Report neck lumps, hoarse voice, or difficulty swallowing to GP immediately. People with personal or family history of medullary thyroid cancer should NOT use these drugs.
Vitamin B12
Screen for depletion, especially if also on metformin. Metformin depletes B12 over years. GLP-1 drugs may add to this risk. Annual testing recommended. Supplement if borderline — neurological damage from B12 deficiency is preventable.
Full blood count (FBC)
Detect anaemia from reduced food intake or B12 depletion. Significant caloric restriction and reduced nutrient absorption may lead to iron or B12 deficiency anaemia over time. Include ferritin if FBC shows low haemoglobin.
Side Effects and Their Blood Test Connections
Most side effects of GLP-1 drugs are gastrointestinal and temporary. Some, however, have specific blood test correlates that need monitoring.
Nausea and vomiting
The most common side effect, especially in the first 4-8 weeks. Typically improves as the body adjusts. Eating smaller meals and avoiding fatty food helps. If vomiting is daily, contact your GP as dehydration can affect kidney function.
Abdominal pain or bloating
Mild abdominal discomfort is common due to delayed gastric emptying. However, severe abdominal pain, especially radiating to the back, with nausea or vomiting, may indicate pancreatitis and requires urgent medical attention.
Constipation or diarrhoea
GLP-1 drugs slow gut motility, causing constipation in many patients. Some experience alternating bowel changes. Staying hydrated and eating adequate fibre helps. Persistent diarrhoea warrants investigation.
Fatigue and reduced energy
Common in the first few months, partly from reduced calorie intake. Check iron, B12, folate, and TSH if fatigue is significant or persistent. Nutritional deficiencies are an under-recognised issue in long-term GLP-1 users.
Hypoglycaemia (low blood sugar)
Rare on GLP-1 drugs alone, but a real risk if you are also on sulphonylureas or insulin. Symptoms include sweating, trembling, dizziness, and confusion. Your GP may need to reduce other diabetes medications as HbA1c improves.
Gallstones
Rapid weight loss increases gallstone formation risk. GLP-1 drugs cause a degree of this. Symptoms include right upper abdominal pain, especially after fatty meals, and may indicate gallstones or biliary sludge. Liver function tests and an ultrasound confirm the diagnosis.
Injection site reactions
Redness, bruising, or lumps at the injection site. Rotate injection sites (abdomen, thigh, upper arm). Persistent lumps or signs of infection (warmth, pus) warrant GP review.
Neck lump or hoarse voice
A rare but important red flag associated with theoretical thyroid C-cell risk. Report any new lump in the neck, hoarse voice, or difficulty swallowing to your GP immediately for thyroid assessment.
Red Flags — When to Seek Urgent Help
These symptoms require same-day GP or emergency review — do not wait for your next scheduled appointment:
Severe abdominal pain radiating to the back
This is the hallmark of acute pancreatitis. Go to emergency. Stop the medication until cleared by a doctor. Pancreatitis can be life-threatening if untreated.
Persistent vomiting for more than 24 hours
Severe dehydration from vomiting can acutely impair kidney function. If you cannot keep fluids down, seek urgent GP review or emergency care. IV fluids may be needed.
New neck lump or hoarse voice
These symptoms could indicate medullary thyroid carcinoma — the rare thyroid cancer flagged in animal studies. See your GP within a day or two for neck examination and thyroid ultrasound.
Jaundice (yellow skin or eyes) or dark urine
Suggests liver involvement. Could be gallstones, bile duct obstruction, or drug-related liver injury. Urgent LFTs and bilirubin, plus hepatology or emergency referral if severe.
Right upper abdominal pain after eating
Classic pattern of gallstones or biliary colic, which is more common with rapid weight loss. Needs ultrasound and surgical referral if confirmed.
Signs of low blood sugar with other diabetes medication
Shakiness, sweating, rapid heartbeat, confusion. GLP-1 drugs potentiate hypoglycaemia when combined with sulphonylureas or insulin. Eat glucose immediately and contact your GP to review medication doses.
Monitoring Schedule — When to Get Each Test
This schedule is based on Australian Diabetes Society guidance and common GP practice. Individual monitoring may be more frequent if you have kidney disease, liver disease, or are on multiple diabetes medications.
Baseline tests before starting
Before your first injection: HbA1c, fasting glucose, lipid panel, full blood count, LFTs, eGFR, creatinine, TSH, vitamin B12. These are your baseline values to measure progress against.
Three-month follow-up
Repeat HbA1c and fasting glucose to confirm blood sugar is improving. Assess tolerance (nausea, vomiting, weight change). Check eGFR if nausea or vomiting has been significant. Dose escalation decisions are made at this point.
Six-month check
Full repeat panel: HbA1c, lipid panel, LFTs, eGFR, lipase (if any abdominal symptoms). Review weight change and medication adherence. Adjust dose or add/remove other medications as needed.
Annual maintenance bloods
Comprehensive annual panel including all baseline markers plus vitamin B12, ferritin, and TSH. This is when long-term issues such as B12 depletion or thyroid changes are most likely to be identified.
After any dose change
Repeat HbA1c 3 months after any dose increase to assess response. Kidney function tests are warranted if gastrointestinal side effects are ongoing at the new dose.
If abdominal pain occurs
Urgent lipase and amylase tests plus liver function tests. Lipase more than 3 times the upper limit of normal with abdominal pain is suggestive of pancreatitis. Imaging (ultrasound or CT) is usually arranged at hospital.
Pre-surgery pause
Current guidance recommends stopping GLP-1 drugs 1 week before elective surgery (daily dosing) or 2-4 weeks before (weekly dosing) due to aspiration risk from delayed gastric emptying. Always inform your anaesthetist you are on these medications.
Lifestyle Strategies to Support Your Treatment
Small, frequent meals
Eating strategyGLP-1 drugs slow gastric emptying, so large meals cause bloating and nausea. Aim for 4-5 small meals per day. Stop eating when full — the medication amplifies satiety signals.
High-protein diet
NutritionAdequate protein (1.2-1.5 g/kg/day) is critical to prevent muscle loss during rapid weight loss. Include chicken, fish, eggs, legumes, and low-fat dairy at every meal.
Avoid fatty and fried foods
NutritionHigh-fat meals worsen nausea and delay gastric emptying further. Reducing dietary fat dramatically improves GI tolerance in the first 8 weeks.
Adequate hydration
SafetyNausea and reduced appetite can lead to inadequate fluid intake. Aim for at least 8 glasses of water daily. Dehydration worsens kidney function and exacerbates constipation.
Resistance exercise
ExerciseWeight loss on GLP-1 drugs includes muscle mass. Resistance training 2-3 times per week helps preserve lean muscle and maintain metabolic rate during weight loss.
Multivitamin and B12 supplement
SupplementationGiven reduced food intake and potential B12 depletion (especially with concurrent metformin), a quality multivitamin including B12, iron, and vitamin D is advisable. Discuss with your GP or dietitian.
Alcohol moderation
LifestyleAlcohol can worsen nausea and increases the risk of low blood sugar if you are on other diabetes medications. It also stresses the liver and pancreas, which you want to monitor on GLP-1 therapy.
Related Reading
Got Your Monitoring Results?
Upload your blood test PDF and SmarterBlood's AI will explain every marker in plain English — HbA1c, lipids, kidney function, liver enzymes — with Australian reference ranges and what each result means for your treatment.
This page provides general educational information about blood test monitoring for GLP-1 receptor agonists. It is not a substitute for professional medical advice. Always follow your prescribing doctor's monitoring schedule and contact them promptly if you experience concerning symptoms. SmarterBlood does not provide medical care.